Summary

This article presents results of the Ranolazine in Atrial Fibrillation Following an Electrical Cardioversion randomized trial [RAFFAELLO; NCT01534962], an international, double-blind, parallel, Phase 2, dose-ranging study testing three oral ranolazine doses. The results demonstrated safety and provided favorable findings with regard to efficacy for patients with atrial fibrillation.